Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 12, 2013, Pages 2707-2714

  Hurt Camejo, Eva ^a   Gautier, Thomas ^a,b   Rosengren, Birgitta ^a   Dikkers, Arne ^a   Behrendt, Margareta ^a   Grass, David S ^c   Rader, Daniel J ^d   Tietge, Uwe J F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c University of Pennsylvania School of Medicine ^*

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apolipoproteins E; Atherosclerosis; Cholesterol, VLDL; Cholesteryl ester transfer proteins; High density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; SECRETORY PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 TYPE IIA; UNCLASSIFIED DRUG; VARESPLADIB; VERY LOW DENSITY LIPOPROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; GENE OVEREXPRESSION; GENE TRANSFER; IN VIVO STUDY; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL, VLDL; CHOLESTERYL ESTER TRANSFER PROTEINS; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL;

ACETATES; ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEIN E3; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, ATHEROSCLEROTIC;

EID: 84888201985     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301410     Document Type: Article

References (38)

1. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(23 suppl 1):III8-II14
2. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193-205
3. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904-913
4. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217
5. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47(8 suppl):C19-C31
6. Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol. 2000;86:718-722
7. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280-1284
8. Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249-1257
9. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009;30:2742-2748
10. Lind L, Simon T, Johansson L, Kotti S, Hansen T, Machecourt J, Ninio E, Tedgui A, Danchin N, Ahlström H, Mallat Z. Circulating levels of secretory-And lipoprotein-Associated phospholipase A2 activities: Relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J. 2012;33:2946-2954
11. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005;25:839-846
12. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: The EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 2007;27:1177-1183
13. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, Rader DJ. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275:10077-10084
14. Tietge UJ, Maugeais C, Cain W, Rader DJ. Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. Am J Physiol Endocrinol Metab. 2003;285:E403-E411
15. de Beer FC, Connell PM, Yu J, de Beer MC, Webb NR, Van Der Westhuyzen DR. HDL modification by secretory phospholipase A(2) promotes scavenger receptor class B type I interaction and accelerates HDL catabolism. J Lipid Res. 2000;41:1849-1857
16. Hakala JK, Oörni K, Pentikäinen MO, Hurt-Camejo E, Kovanen PT. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol. 2001;21:1053-1058
17. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis AJ, Berliner JA. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999;19:1291-1298
18. Tietge UJF, Pratico D, Ding T, Funk CD, Hildebrand RB, van Berkel TJ, van Eck M. Macrophage-specific expression of type iia secretory phospholipase a2 results in accelerated early atherogenesis by increasing oxidative stress in ldl-receptor deficient mice. J Lipid Res. 2005;46:1604-1614
19. Van Der Giet M, Tölle M, Pratico D, Lufft V, Schuchardt M, Hörl MP, Zidek W, Tietge UJ. Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease. J Mol Med (Berl). 2010;88:75-83
20. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F, Lusis AJ. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol. 1999;19:1284-1290
21. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J. 2012;33:2899-2909
22. de Beer FC, de Beer MC, Van Der Westhuyzen DR, Castellani LW, Lusis AJ, Swanson ME, Grass DS. Secretory non-pancreatic phospholipase A2: Influence on lipoprotein metabolism. J Lipid Res. 1997;38:2232-2239
23. Kinoshita M, Arai H, Fukasawa M, Watanabe T, Tsukamoto K, Hashimoto Y, Inoue K, Kurokawa K, Teramoto T. Apolipoprotein E enhances lipid exchange between lipoproteins mediated by cholesteryl ester transfer protein. J Lipid Res. 1993;34:261-268
24. Jönsson-Rylander AC, Lundin S, Rosengren B, Pettersson C, Hurt-Camejo E. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep. 2008;10:252-259
25. de Beer FC, Webb NR. Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol. 2006;26:1421-1422
26. Anthera Halts VISTA-16 Clinical Study Due to Lack of Efficacy Following Recommendation by the Independent Data Safety Monitoring Board [press release]. Hayward, CA: Anthera Pharmaceuticals, Inc; March 9, 2012
27. Rader DJ. Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein. Curr Atheroscler Rep. 2004;6:398-405
28. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006;17:394-398
29. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, highdensity lipoproteins, and reverse cholesterol transport. Annu Rev Nutr. 1998;18:297-330
30. Lagrost L, Barter PJ. Effects of various non-esterified fatty acids on the transfer of cholesteryl esters from HDL to LDL induced by the cholesteryl ester transfer protein. Biochim Biophys Acta. 1991;1085:209-216
31. Fielding CJ, Reaven GM, Liu G, Fielding PE. Increased free cholesterol in plasma low and very low density lipoproteins in non-insulin-dependent diabetes mellitus: Its role in the inhibition of cholesteryl ester transfer. Proc Natl Acad Sci U S A. 1984;81:2512-2516
32. Morton RE. Free cholesterol is a potent regulator of lipid transfer protein function. J Biol Chem. 1988;263:12235-12241
33. Zak Z, Gautier T, Dumont L, Masson D, Deckert V, Duverneuil L, Pais De Barros JP, Le Guern N, Schneider M, Moulin P, Bataillard A, Lagrost L. Effect of cholesteryl ester transfer protein (CETP) expression on diet-induced hyperlipidemias in transgenic rats. Atherosclerosis. 2005;178:279-286
34. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies. Biochim Biophys Acta. 1994;1215:209-236
35. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164
36. Rigotti A, Edelman ER, Seifert P, Iqbal SN, DeMattos RB, Temel RE, Krieger M, Williams DL. Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem. 1996;271:33545-33549
37. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res. 2004;45:1169-1196
38. Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009;20:327-332